We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Tcr2 Therapeutics Inc
9 own
8 watching
Current Price
$1.48
$0.1
(7.25%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
57.21M
52-Week High
3.88
52-Week Low
0.821
Average Volume
0.18M
Dividend Yield
--
P/E Ratio
16.9366
Market Capitalization57.21M52-Week High3.8852-Week Low0.821Average Volume0.18MDividend Yield--P/E Ratio16.9366What does the Tcr2 Therapeutics Inc do?
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. The company's lead product candidates include TC-210, mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which initiated in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma; and TC-110 a TRuC-T cell targeting CD19-positive B-Cell hematological malignancies. Its product candidates in pipeline comprise TC-220, a TRuC-T cell that targets MUC16 positive solid tumors; TC-310, a dual TRuC-T cells targeting both CD19 and CD22; and TC-410, a dual TRuC-T cell targeting both mesothelin and MUC16. The company has a cooperative research and development agreement with the National Cancer Institute to collaborate on the use of TCR2 proprietary T cell receptor Fusion Construct T cells as a cancer therapeutic agent against mesothelin in Phase I/II clinical trial of TC-210. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Read More
How much money does Tcr2 Therapeutics Inc make?
News & Events about Tcr2 Therapeutics Inc.
Globe Newswire
24days ago
gavo-cel Phase 2 clinical trial now focused on ovarian cancer cohort with first meaningful durability data expected in 2H 2023Second-generation enhanced programs TC-510 and TC-520 prioritized with TC-510 Phase 1 clinical trial ongoing and first meaningful objective response data expected in 2H ...
Globe Newswire
2 months ago
CAMBRIDGE, Mass., Nov. 23, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced that management will participate in a fireside chat at the 34th Annual ...
Globe Newswire
2 months ago
CAMBRIDGE, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced the poster presentation of new preclinical data at the Society for ...
Ticker Report
5 months ago
TCR2 Therapeutics Inc. (NASDAQ:TCRR Get Rating) saw a large increase in short interest during the month of July. As of July 15th, there was short interest totalling 2,070,000 shares, an increase of 21.1% from the June 30th total of 1,710,000 shares. Approximately 7.0% of the shares of the ...
PR Newswire
10 months ago
Thinking about buying stock in Draganfly, Enservco, Avinger, Hall of Fame Resort & Entertainment, or Tcr2 Therapeutics? Thinking about buying stock in Draganfly, Enservco, Avinger, Hall of Fame Resort & Entertainment, or Tcr2 Therapeutics? PR Newswire NEW YORK, March 22, 2022 NEW...
Frequently Asked Questions
Frequently Asked Questions
What is Tcr2 Therapeutics Inc share price today?
Can Indians buy Tcr2 Therapeutics Inc shares?
How can I buy Tcr2 Therapeutics Inc shares from India?
Can Fractional shares of Tcr2 Therapeutics Inc be purchased?
What are the documents required to start investing in Tcr2 Therapeutics Inc stocks?
What is today’s traded volume of Tcr2 Therapeutics Inc?
What is today’s market capitalisation of Tcr2 Therapeutics Inc?
What is the 52-Week High and Low Range of Tcr2 Therapeutics Inc?
What percentage is Tcr2 Therapeutics Inc down from its 52-Week High?
What percentage is Tcr2 Therapeutics Inc up from its 52-Week Low?
Current Price
$1.48
$0.1
(7.25%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.